CareDx Inc. (CDNA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
CareDx Inc. (CDNA) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How CDNA Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $379.8M | 44% | -8.1% | -$21.4M | $24.9M | -8.5% |
| FY 2024 | $333.8M | 44% | 12.2% | $52.5M | $23.0M | 10.2% |
| FY 2023 | $280.3M | 44% | -72.5% | -$190.3M | -$31.0M | -13.1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CDNA)
- ✓Live walkthrough of CDNA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CDNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +13.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CDNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CDNA. Explore sector supply chains on /butterfly.
CDNA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is CareDx Inc. (CDNA)?
In FY 2025 (10-K), CDNA converted $379.8M of revenue into a 44% gross margin, 0% operating margin, and $24.9M in free cash flow (6.6% FCF margin).